Home » Evotec Starts Phase I With EVT 103
Evotec Starts Phase I With EVT 103
Evotec AG announced Tuesday the Phase I clinical study initiation for EVT 103, a small molecule NR2B-selective NMDA receptor antagonist. EVT 103 is a next generation molecule following EVT 101, the orally available compound currently planned to enter clinical development for treatment-resistant depression in collaboration with Roche.
Fox Business
Fox Business
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May